Scientists at Purdue University and France's Institut de Cancérologie de L'Ouest (ICO) have discovered that glyphosate, the primary ingredient in some widely used herbicides and pesticides, can lead to breast cancer under certain conditions. The discovery is another step forward when it comes to determining how cancer starts, and how it can be prevented. WEST LAFAYETTE, Ind. — Scientists know that the solution to preventing breast cancer won't come easily, but a collaborative team of scientists at Purdue University and the Institut National de la Santé et de la Recherche Médicale (INSERM)/Institut de Cancérologie de L'Ouest (ICO) in Nantes, France, say they've recently discovered one of the missing pieces of the puzzle when it comes to cancer prevention.
The Purdue Center for Cancer Research, working with ICO, the Cancer Center for Western France, as part of a memorandum of agreement with the Purdue-led International Breast Cancer and Nutrition (IBCN) initiative, discovered that glyphosate, the primary ingredient in widespread herbicides, can lead to mammary cancer when combined with another risk factor. The work was published in Frontiers in Genetics.
"This is a major result and nobody has ever shown this before," says Sophie Lelièvre, a professor of cancer pharmacology in Purdue's College of Veterinary Medicine and co-leader of IBCN. "Showing that glyphosate can trigger tumor growth, when combined with another frequently observed risk, is an important missing link when it comes to determining what causes cancer. "
Scientists exposed noncancerous human mammary epithelial cells to glyphosate in vitro over a course of 21 days. The cells were then placed in mice to assess tumor formation. Although cells exposed to glyphosate alone did not induce tumor growth, cancerous tumors did develop after glyphosate was combined with molecules that were linked to oxidative stress. Oxidative stress is a chemical reaction that occurs as the result of aging, diet, alcohol consumption, smoking or other stressors, and it alters the organization and integrity of the genome of the breast, aiding cancer development.
"What was particularly alarming about the tumor growth was that it wasn't the usual type of breast cancer we see in older women," Lelièvre (pronounced Le-LEE-YEA-vre) said. "It was the more aggressive form found in younger women, also known as luminal B cancer."
Glyphosate has been the subject of widespread scientific debate when it comes to cancer research. The U.S. Environmental Protection Agency said in a 2017 risk assessment that the herbicide was likely not carcinogenic. However, in 2015, the World Health Organization's International Agency for Research on Cancer said glyphosate was "probably carcinogenic." Research that was published in 2017 also associated glyphosate with non-Hodgkin lymphoma.
Another key discovery researchers made was the ability to identify the pathway, at the epigenetic level (i.e., the chemical marks on DNA and proteins that control gene expression), used by glyphosate to endanger breast cells. Lelièvre and Gwenola Bougras-Cartron, the lead scientist on the project from ICO, hope this evidence will enable researchers to both detect and reverse the risk for breast cancer when associated with this combination of risk factors.
"There is a huge gap in the research that is targeted at understanding why cancer develops," Lelièvre said. "This discovery is novel, primarily because until now, there hasn't been any scientific evidence to show that a second factor when associated with common pollutants would be sufficient for cancer to develop. It's very difficult to determine what causes breast cancer, but this is a critical step forward in the right direction so we can start working toward prevention as we have outlined in the international collaborative work of IBCN (www.purdue.edu/breastcancer)."
Cancer incidence continues to rise globally, with breast cancer being the most common type, according to Cancer.gov. Lelièvre said those facts alone continue to fuel the motivation for her research with the hope of eventually finding a way to prevent cancer before it even starts.
"There has been a heavy focus on research for both treatment and detection, but prevention just isn't as prevalent," Lelièvre said. "If we can find a way to mitigate the risks, we can have hope for fewer cases."
The work was funded by the National League Against Cancer in France (Ligue Nationale Contre le Cancer).
Lelièvre is a proponent of state-of-the-art cell culture models that replicate different phases of cancer development for research and she has been working with a team of researchers at Purdue to develop a device, with funding from the Congressionally-Directed Medical Research Program/Breast Cancer Research Program, that will help identify risk factors and underlying mechanisms that cause breast cancer. She is also working with researchers to create tumor models in 10 days that are much closer in size to the ones found in the human body to help test new therapies and screen for drug sensitivity.
This work aligns with Purdue's Giant Leaps celebration of the university's global advancements in health as part of Purdue's 150th anniversary. It is one of the four themes of the yearlong celebration's Ideas Festival, designed to showcase Purdue as an intellectual center solving real-world issues.
